Skip to content

H2020FP7HORIZON

Bristol-Myers Squibb Company Corp

Country
USUnited States
Defence projects
0
Projects, all programmes
23
As coordinator
0
EU contribution (CORDIS)
EUR 57,572
Active
2010 to 2025

Projects

23 projects, newest first

Projects, newest first
ProjectProgrammeYearRoleEU contribution
READIResearch in Europe and Diversity InclusionHORIZON2025ParticipantEUR 0
VICT3RDeveloping and implementing VIrtual Control groups To reducE animal use in toxicology ResearchHORIZON2024ParticipantEUR 0
SYNTHIASynthetic Data Generation Framework for Integrated Validation of Use Cases and AI Healthcare ApplicationsHORIZON2024ParticipantEUR 0
GUIDE.MRDGUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRDHORIZON2023ParticipantEUR 0
CLAIMSCLinical impact through AI-assisted MS careHORIZON2023ParticipantEUR 0
FACILITATEFrAmework for ClInicaL trIal participants daTA reutilization for a fully Transparent and Ethical ecosystemH20202022ParticipantEUR 0
HIPPOCRATESHealth Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European StatesH20202021ParticipantEUR 0
PREMIERPrioritisation and Risk Evaluation of Medicines in the EnviRonmentH20202020ParticipantEUR 0
ARDATAccelerating Research & Development for Advanced TherapiesH20202020ParticipantEUR 0
IDEA-FASTIdentifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseasesH20202019ParticipantEUR 0
ConcePTIONBuilding an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generationH20202019ParticipantEUR 0
NECESSITYNEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patientsH20202019ParticipantEUR 0
3TRIdentification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic ConditionsH20202019ParticipantEUR 0
LITMUSLiver Investigation: Testing Marker Utility in SteatohepatitisH20202017ParticipantEUR 0
RTCureRheuma Tolerance for CureH20202017ParticipantEUR 0
IPIEIntelligent Assessment of Pharmaceutical in the EnvironmentFP72015ParticipantNot stated
GETREALIncorporating real-life clinical data into drug developmentFP72013ParticipantNot stated
EUPATIEuropean Patients' Academy on Therapeutic InnovationFP72012ParticipantNot stated
ORBITOOral biopharmaceutics toolsFP72012ParticipantNot stated
MIP-DILIMechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver InjuryFP72012ParticipantNot stated

The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.

Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.